Table 1.
Race-specific associations between GReX of GReX-prioritized genes and CRS. Effect estimates correspond to change in CRS per one SD increase in GReX, adjusted for age, ER status, stage, and CBCS study phase. Ninety-five percent confidence intervals of effect sizes are provided. All GReX-prioritized gene and CRS pairs shown here showed overall association FDR-adjusted P < 0.10 and FDR-adjusted permutation P < 0.05 (across 5,000 permutations of the SNP-gene weights). We also provide signatures that include these genes as reference (Supplementary Table S1).
| WW (N = 1,043) | BW (N = 1,083) | ||||||
|---|---|---|---|---|---|---|---|
| Gene | Signature | ROR-S | Proliferation | ROR-P | ROR-S | Proliferation | ROR-P |
| MCM10 | IGF | 3.03 (1.73, 4.33) | 0.06 (0.03, 0.08) | 3.11 (1.72, 4.50) | — | — | — |
| FAM64A | IGF | 2.57 (1.28, 3.86) | 0.05 (0.02, 0.07) | 2.64 (1.26, 4.02) | — | — | — |
| CCNB2 | Estradiol | 2.69 (1.40, 3.98) | 0.05 (0.02, 0.08) | 2.71 (1.33, 4.09) | — | — | — |
| MMP1 | Estradiol | 2.73 (1.45, 4.01) | 0.05 (0.02, 0.07) | 2.58 (1.21, 3.96) | −1.84 (−3.12, −0.56) | −0.04 (−0.07, −0.02) | −2.21 (−3.56, −0.87) |
| VAV3 | Other | −2.22 (−3.51, −0.93) | −0.04 (−0.07, −0.02) | −2.40 (−3.79, −1.03) | — | — | — |
| PCSK6 | IGF | −2.16 (−3.45, −0.88) | −0.03 (−0.06, 0.00) | −1.88 (−3.25, −0.50) | — | — | — |
| GNG11 | Claudin-low | −1.27 (−2.56, 0.02) | −0.02 (−0.05, 0.00) | −1.42 (−2.80, −0.05) | — | — | — |